The compound you described, 1-[2-[2,5-dimethyl-1-(phenylmethyl)-3-pyrrolyl]-2-oxoethyl]pyrrolidine-2,5-dione, is a complex organic molecule with a specific structure. It's important to understand that its structure is essential to understanding its properties and potential applications in research.
**Here's a breakdown of the compound's components and their significance:**
* **Pyrrolyl:** The pyrrolyl part refers to a pyrrole ring, a five-membered heterocyclic ring containing one nitrogen atom. Pyrrole rings are commonly found in naturally occurring molecules like heme (in hemoglobin) and chlorophyll.
* **2,5-Dimethyl-1-(phenylmethyl)-3-pyrrolyl:** This part describes a specific pyrrole ring substituted with two methyl groups (CH3) at positions 2 and 5, and a benzyl group (CH2-Ph, where Ph represents a phenyl ring) at position 1. These substitutions influence the molecule's reactivity and properties.
* **2-oxoethyl:** This part refers to a ketone group (-COCH2-) connected to the pyrrole ring. Ketones are important functional groups in organic chemistry, often involved in reactions and contributing to a molecule's reactivity.
* **Pyrrolidine-2,5-dione:** This is the structure of succinimide, a cyclic imide that is known for its stability and potential to act as a scaffold for other molecules.
**Importance in Research**
The compound you described likely has potential research applications due to its unique structure:
* **Potential Biological Activity:** The combination of a pyrrole ring, a ketone group, and a succinimide ring suggests possible biological activity. Pyrrole derivatives are known to exhibit a wide range of pharmacological properties, including anti-inflammatory, antimicrobial, and antitumor activities. The presence of the succinimide ring might contribute to the molecule's ability to bind to biological targets.
* **Potential Synthetic Utility:** The compound could serve as a building block or intermediate in the synthesis of other more complex molecules with desired biological or chemical properties.
**To determine the specific importance of this compound in research, you would need more information, such as:**
* **What research area is it being studied in?** (e.g., medicine, materials science, etc.)
* **What specific properties or activities are being investigated?** (e.g., anti-cancer activity, fluorescence properties, etc.)
Without this context, it's impossible to provide a definitive answer regarding the compound's specific importance in research.
ID Source | ID |
---|---|
PubMed CID | 2113511 |
CHEMBL ID | 1404553 |
CHEBI ID | 92682 |
SCHEMBL ID | 17385567 |
Synonym |
---|
HMS1753L14 |
smr000068650 |
MLS000057725 , |
ml031 |
SR-01000066488-3 |
1-[2-(1-benzyl-2,5-dimethylpyrrol-3-yl)-2-oxoethyl]pyrrolidine-2,5-dione |
AKOS007958482 |
HMS2375P22 |
bdbm41648 |
1-[2-[2,5-dimethyl-1-(phenylmethyl)-3-pyrrolyl]-2-oxoethyl]pyrrolidine-2,5-dione |
cid_2113511 |
1-[2-[2,5-dimethyl-1-(phenylmethyl)pyrrol-3-yl]-2-oxidanylidene-ethyl]pyrrolidine-2,5-dione |
1-[2-(1-benzyl-2,5-dimethyl-pyrrol-3-yl)-2-keto-ethyl]pyrrolidine-2,5-quinone |
852230-33-2 |
CHEMBL1404553 |
SCHEMBL17385567 |
CHEBI:92682 |
SR-01000066488-1 |
sr-01000066488 |
Z19746470 |
cym-5482 |
1-(2-(1-benzyl-2,5-dimethyl-1h-pyrrol-3-yl)-2-oxoethyl)pyrrolidine-2,5-dione |
Q27164385 |
AS-16650 |
ml-031 |
CS-0034849 |
CJB23033 |
HY-111292 |
1-[2-(1-benzyl-2,5-dimethyl-1h-pyrrol-3-yl)-2-oxoethyl]pyrrolidine-2,5-dione |
EN300-117401 |
Class | Description |
---|---|
aromatic ketone | A ketone in which the carbonyl group is attached to an aromatic ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 56.2341 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 37.9330 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 21.1446 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 17.3582 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 1.4125 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 7.0795 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 19.9526 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 35.4813 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 17.7828 | 0.0079 | 8.2332 | 1,122.0200 | AID2546 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 0.0891 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 3.5481 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
sphingosine 1-phosphate receptor 2 | Homo sapiens (human) | EC50 (µMol) | 22.6010 | 1.2020 | 1.2020 | 1.2020 | AID872; AID874 |
Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) | EC50 (µMol) | 2.8530 | 0.0007 | 0.3651 | 2.8530 | AID854 |
Histamine H1 receptor | Cavia porcellus (domestic guinea pig) | EC50 (µMol) | 1.2020 | 0.0026 | 0.5334 | 1.2020 | AID872 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
G protein-coupled receptor binding | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
G protein-coupled receptor activity | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
integrin binding | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
protein binding | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
lipid binding | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
G protein-coupled peptide receptor activity | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
sphingosine-1-phosphate receptor activity | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
postsynapse | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
plasma membrane | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
cytoplasm | Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) |
plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |